August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...